Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/ dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort.

被引：0
|
作者：
Mailly-Giacchetti, Leah
Colle, Raphael
Ataz, Daniel Lopez-Trabada
Duval, Alex
Andre, Thierry
Cohen, Romain
机构：
[1] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Med Oncol, Paris, France
[2] St Antoine Hosp, Dept Med Oncol, Paris, France
[3] Sorbonne Univ, INSERM, Unite Mixte Rech Sci 938, Paris, France
[4] Ctr Rech St Antoinee, Site Rech Integree Canc SIRIC, CURAMUS, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
795
引用
收藏
页码：795 / 795
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (01) : 47 - 54
  • [22] Safety and efficacy of pembrolizumab monotherapy in patients with advanced colorectal MSI-h/dMMR cancers.
    Michalaki, Vasiliki
    Polydorou, Andreas
    Dafnios, Nikolaos
    Theodosopoulos, Theodosios
    Vezakis, Antonios
    Iliakopoulos, Konstantinos
    Karandrea, Despina
    Papadimitriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] The efficacy of immune checkpoint inhibitors in patients with cancer with pseudoprogression
    Lyadova, Marina
    Fedorinov, Denis
    Pardabekova, Olesya
    Nosova, Margarita
    Tuleiko, Veronika
    Lyadov, Vladimir
    Kuzmina, Evgenia
    Antonova, Tatiana
    Lyadov, Konstantin
    Galkin, Vsevolod
    Poddubnaya, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Efficacy of immune checkpoint inhibitors and age in cancer patients
    Huang, Xuan-zhang
    Gao, Peng
    Song, Yong-xi
    Sun, Jing-xu
    Chen, Xiao-wan
    Zhao, Jun-hua
    Wang, Zhen-ning
    IMMUNOTHERAPY, 2020, 12 (08) : 587 - 603
  • [25] Comparative efficacy, safety, and tolerability of immune checkpoint inhibitors (ICIs) in cancer.
    Al-Showbaki, Laith
    Nadler, Michelle
    Desnoyers, Alexandra
    Almugbel, Fahad
    Cescon, David W.
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Immune checkpoint inhibitors/ImmunosuppressantsVarious toxicities and lack of efficacy: 32 case reports
    Reactions Weekly, 2024, 2038 (1) : 157 - 157
  • [27] Immune checkpoint inhibitors and immunosuppressantsVarious toxicities and lack of efficacy: 23 case reports
    Reactions Weekly, 2021, 1876 (1) : 165 - 165
  • [28] A Review of the Patterns of Prescribing, Efficacy and Toxicities for Patients Receiving Checkpoint Inhibitors
    Nightingale, P.
    Parente, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 68 - 68
  • [29] Immune checkpoint inhibitors/immune globulin/prednisoneVarious toxicities and lack of efficacy: 7 case reports
    Reactions Weekly, 2022, 1907 (1) : 249 - 249
  • [30] Impact of gender on the efficacy of immune checkpoint inhibitors for urological cancers: A systematic review and meta-analysis
    Yanagiswawa, T.
    Kawada, T.
    Quhal, F.
    Bekku, K.
    Laukhtina, E.
    Rajwa, P.
    Von Deimling, M.
    Majdoub, M.
    Chlosta, M.
    Pradere, B.
    Mori, K.
    Kimura, T.
    Schmidinger, M.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2023, 83 : S484 - S485
12345